Shanghai, October 27, 2020 - 3D Medicines, Inc. (3D Medicines) and Shanghai Haihe Pharmaceutical Co.,Ltd (Haihe Biopharma) today announced a collaboration agreement on Haihe Biopharma‘s innovative analgesics of RMX1001 and RMX1002. 3D Medicines will obtain the exclusive authorization for R&D, production and commercialization of RMX1001 and RMX1002 in China，which was an important move for 3D Medicines to envision a future when cancer is managed as a chronic disease, helping to further form a highly complementary pipeline of 3D Medicines.

RMX1001 is a Cox-2 inhibitor. Compared with traditional non-steroidal anti-inflammatory drugs（(NSAIDs), RMX1001 has better safety, tolerability and significant analgesic characteristics. RMX1002 is an EP4 receptor antagonist that is safe, fast-acting and shows sustained analgesic effect. Both drugs are expected to replace traditional non-steroidal anti-inflammatory drugs as new analgesics.

Prior to this, RMX Biopharma，Haihe Biopharma’s subsidiary，in-licensed the China rights for R&D, production and commercialization of two drugs from AskAt Inc. in Japan and completed Phase I clinical trials in China. Next, 3D Medicines will steadily advance the clinical trials, and strive to achieve the earlier marketing application of two new analgesics to help patients reduce pain and improve their quality of life.

John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines, commented: “We are very glad to work with Haihe Biopharma again. As a  non-opioid analgesics with fewer side effects and better efficacy, we believe that RMX1001 and RMX1002 can relieve pain for patients and bring better quality of life. This is highly consistent with the company's philosophy: help people with cancer live longer and better.”

Dr. Ruiping Dong, CEO of Haihe Biopharma, said, "We are very pleased to cooperate with 3D Medicines again. RMX1001 and RMX1002 target upstream and downstream targets in the same pathway, while improving safety and showing strong analgesic characteristics. We look forward to patient’s better treatment options provided by these two products in the field of non-opioid analgesia."

About 3D Medicines

3D Medicines, Inc. is a clinical-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with innovative biological and small-molecule anti-cancer drugs, as well as a professional team capable of global development, registration and commercialization operation. 

About Haihe Biopharma

Haihe Biopharma focuses on discovery, development and commercialization of innovative anti-tumor drugs. Guided by our mission, "Inclusive and open to diversity, innovation oriented to win together and benefit the mankind", Haihe Biopharma insists on the way of independent innovation and pursues global development of China originated innovative drugs.

The company is led by an academician of the Chinese Academy of Engineering. The senior management team has extensive experiences in drug research and development in China and abroad. Haihe Biopharma has built a precision medical platform guided by biomarkers, and established a fully integrated pre-clinical evaluation technical platform and clinical study system for innovative drugs, with advanced technology and operation in consistence with international standards and norms, covering subunits from compound synthesis, CMC study, biomarker discovery and validation, medical strategy and clinical study, etc. The company has established a globally competitive innovative drug R&D system and robust product pipeline. There are 7 compounds in clinical and 3 compounds in preclinical studies.